Achilles Therapeutics Management
Management criteria checks 2/4
Achilles Therapeutics' CEO is Iraj Ali, appointed in Jan 2018, has a tenure of 8.83 years. total yearly compensation is $1.70M, comprised of 27.3% salary and 72.7% bonuses, including company stock and options. directly owns 2.71% of the company’s shares, worth $1.27M. The average tenure of the management team and the board of directors is 5.6 years and 4.7 years respectively.
Key information
Iraj Ali
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 27.3% |
| CEO tenure | 7yrs |
| CEO ownership | 2.7% |
| Management average tenure | 5.6yrs |
| Board average tenure | 4.7yrs |
Recent management updates
Recent updates
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?
Sep 20
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?
Feb 26Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Nov 13Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Jul 19Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?
Mar 11Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Nov 18Achilles-led group gets €4M funding for personalized cell therapy manufacturing
Jul 21Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?
Apr 13Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans
Dec 27Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Sep 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$67m |
| Jun 30 2024 | n/a | n/a | -US$64m |
| Mar 31 2024 | n/a | n/a | -US$64m |
| Dec 31 2023 | US$2m | US$463k | -US$70m |
Compensation vs Market: Iraj's total compensation ($USD1.70M) is above average for companies of similar size in the US market ($USD649.25K).
Compensation vs Earnings: Insufficient data to compare Iraj's compensation with company performance.
CEO
Iraj Ali (49 yo)
7yrs
Tenure
US$1,698,000
Compensation
Dr. Iraj Ali, Ph.D. serves as Chief Executive Officer at Achilles Therapeutics Plc since December 10, 2018 and served as its Interim Chief Executive Officer since January 2018 until December 10, 2018. Dr....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$1.70m | 2.71% $ 1.3m | |
| Founder & Chief Scientific Officer | 9yrs | no data | 1.12% $ 526.5k | |
| Chief Financial Officer | 4.2yrs | no data | 0.66% $ 307.3k | |
| Founder & Member of Scientific Advisory Board | 9yrs | no data | no data | |
| Founder & Member of Scientific Advisory Board | 9yrs | no data | no data | |
| Vice President of Investor Relations & External Communications | 4.1yrs | no data | no data | |
| General Counsel & Company Secretary | 2.2yrs | no data | no data | |
| Head of Communications | no data | no data | no data | |
| Executive Vice President of People | no data | no data | no data | |
| Executive Vice President of Technical Operations | no data | no data | no data | |
| Executive Vice President of Supply Operations | no data | no data | no data | |
| Chief Business Officer | 3yrs | no data | no data |
5.6yrs
Average Tenure
50.5yo
Average Age
Experienced Management: ACHL's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 8.8yrs | US$1.70m | 2.71% $ 1.3m | |
| Founder & Member of Scientific Advisory Board | less than a year | no data | no data | |
| Founder & Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Chairman of the Board | 6.1yrs | US$379.00k | 0.55% $ 257.9k | |
| Independent Non-Executive Director | 4.8yrs | US$176.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
| Independent Non-Executive Director | 6.3yrs | US$189.00k | 0.11% $ 53.2k | |
| Founder & Member of Scientific Advisory Board | less than a year | no data | 1.36% $ 638.6k | |
| Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data |
4.7yrs
Average Tenure
58yo
Average Age
Experienced Board: ACHL's board of directors are considered experienced (4.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 22:32 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Achilles Therapeutics plc is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Ingrid Gafanhão | Bryan Garnier & Co |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |